Hims & Hers Health Inc. said it will enter the Canadian market in 2026, marking the telehealth company’s first expansion outside the United States. The San Francisco-based firm plans to launch its prescription weight-loss program when generic versions of semaglutide become available globally next year. Branded formulations of the diabetes and obesity treatment currently cost more than C$200 a month in Canada; the company expects generics to be "significantly cheaper," broadening access to its service. Hims & Hers added that the Canada move follows the completion of its acquisition of digital health provider ZAVA and forms part of a wider strategy to combine organic growth with select deals to extend its category leadership.